# Tolerability and Efficacy of Modified VCD Regimens in Previously Untreated Multiple Myeloma.

> **NCT02086942** · PHASE2 · UNKNOWN · sponsor: **Yongping Zhai** · enrollment: 94 (estimated)

## Conditions studied

- Multiple Myeloma

## Interventions

- **DRUG:** Bortezomib
- **DRUG:** cyclophosphamide
- **DRUG:** Dexamethasone

## Key facts

- **NCT ID:** NCT02086942
- **Lead sponsor:** Yongping Zhai
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2013-08
- **Primary completion:** 2017-08
- **Final completion:** 2017-08
- **Target enrollment:** 94 (ESTIMATED)
- **Last updated:** 2017-08-29


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02086942

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02086942, "Tolerability and Efficacy of Modified VCD Regimens in Previously Untreated Multiple Myeloma.". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT02086942. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*